Compare Abbott Laboratories (ABT) vs Open Text Corporation (OTEX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Open Text Corporation — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while Open Text Corporation trades at $22.59 (market cap $5.65B). The key difference: Abbott Laboratories is far larger — about 29.5× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| ABT | OTEX | |
|---|---|---|
Market Cap | $166.94B | $5.65B |
Sector | Health | Technology |
52-Week High | $136.62 | $39.69 |
52-Week Low | $82.57 | $20.01 |
Enterprise Value | $193.69B | $10.81B |
Dividend Yield | 2.63% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
OTEX trades at $22.57, down 2.04% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.95 and net income margin of 9.91%, supported by recent earnings beats. Recent news highlights strategic investments in AI and sovereign cloud in Europe, alongside a dividend payment scheduled for June 19, 2026.
The outlook is mixed; analyst consensus targets $29.75 (31.8% upside) with 42% buy ratings, but technical indicators suggest near-term pressure. Risks include execution of growth initiatives and market volatility. The stock presents a value opportunity if AI investments drive future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
